BioTools Innovator VANGUARD and BARDA Launch ReadyDetect Competition to Advance At-Home Blood Collection Technologies
BioTools Innovator VANGUARD, in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), has announced the launch of the ReadyDetect: Blood Sampling Competition, a new initiative designed to accelerate the development of innovative blood self-collection and sample preparation technologies. The competition seeks to support innovators creating solutions that can make diagnostic testing more accessible in homes, community settings, remote locations, and emergency response environments.
The program reflects a growing emphasis on decentralized healthcare and the need for diagnostic technologies that can function outside traditional clinical settings. By encouraging the development of user-friendly blood collection systems, ReadyDetect aims to help improve access to testing, strengthen public health preparedness, and support rapid responses to future health emergencies.
Applications for the competition’s initial Concept Stage are now open and will be accepted through July 31, 2026. The initiative offers significant financial support for innovators whose technologies demonstrate the potential to transform blood collection and sample preparation processes for diagnostic applications.
Addressing the Growing Need for Decentralized Diagnostics
Healthcare systems worldwide are increasingly moving toward decentralized models of care that allow patients to access medical services beyond hospitals, clinics, and laboratories. The COVID-19 pandemic highlighted the importance of scalable testing infrastructure and demonstrated how home-based and community-based diagnostic solutions can play a critical role during public health emergencies.
Despite advances in diagnostic technologies, blood collection remains a significant challenge in decentralized environments. Traditional blood sampling often requires trained healthcare personnel, specialized equipment, and access to clinical facilities. These requirements can limit testing accessibility, particularly in rural areas, underserved communities, emergency situations, and field operations.
The ReadyDetect competition seeks to address these challenges by encouraging the development of technologies that allow individuals to collect blood samples safely and effectively on their own. Such innovations could make diagnostic testing more convenient, reduce dependence on healthcare infrastructure, and increase the availability of testing during outbreaks, disasters, and other public health crises.
By supporting next-generation blood collection solutions, the initiative aims to help bridge the gap between advanced diagnostic capabilities and the practical realities of testing in decentralized settings.
Focus on Capillary Blood Collection and Processing
A central objective of the competition is the development of technologies capable of enabling low-cost and easy-to-use capillary blood collection.
Capillary blood sampling typically involves obtaining a small blood sample through a fingerstick or similar minimally invasive procedure. While this approach is widely used in certain applications, many existing methods still require careful handling and additional processing before samples can be analyzed using laboratory or point-of-care diagnostic systems.
ReadyDetect is specifically seeking innovations that not only facilitate blood collection but also support the preparation of samples into serum and/or plasma. These processed sample types are commonly required for a broad range of diagnostic tests, including those used to detect infectious diseases, monitor chronic conditions, evaluate immune responses, and assess various biomarkers.
The competition emphasizes technologies that can reliably prepare samples in a manner compatible with downstream diagnostic platforms. This compatibility is critical because collected samples must meet quality standards necessary for accurate testing and interpretation.
Innovators participating in the program are encouraged to develop solutions that simplify the collection and processing workflow while maintaining analytical reliability.
Supporting Public Health and National Preparedness
Beyond improving healthcare access, the ReadyDetect initiative is closely aligned with broader goals related to public health preparedness and health security.
Rapid access to diagnostic testing is a cornerstone of effective responses to infectious disease outbreaks, emerging biological threats, and other public health emergencies. During crises, traditional laboratory networks can become overwhelmed, and access to testing resources may be limited by geography, staffing shortages, or logistical constraints.
Self-collection technologies that allow individuals to obtain high-quality blood samples outside clinical environments could significantly expand testing capacity during emergency situations. These capabilities may support earlier detection of disease outbreaks, improve surveillance efforts, and enable more efficient allocation of healthcare resources.
By investing in innovative sample collection technologies today, organizers hope to strengthen the nation’s readiness for future health challenges while simultaneously improving access to routine diagnostic services.
The competition therefore represents both an innovation initiative and a strategic effort to enhance healthcare resilience.
Two-Stage Competition Structure
ReadyDetect has been designed as a two-stage competition that supports technologies at different levels of development.
The first phase, known as the Concept Stage, focuses on early-stage ideas and enabling technologies. Participants are asked to present development plans outlining how their concepts could evolve into functional prototypes suitable for future evaluation.
This stage provides innovators with an opportunity to demonstrate the scientific rationale, technical feasibility, and potential impact of their proposed solutions.
The second phase, referred to as the Prototype Stage, is focused on the development and demonstration of working technologies. Participants in this phase will be expected to provide evidence that their solutions can perform key functions related to blood collection and sample preparation.
Importantly, participation in the Concept Stage is not required in order to apply for the Prototype Stage. This structure allows both emerging innovators and more advanced developers to participate according to their technology readiness level.
The flexibility of the program is intended to attract a wide range of participants and encourage diverse approaches to solving the challenges associated with decentralized blood collection.
Significant Prize Funding Available
To support innovation and accelerate technology development, the ReadyDetect competition offers substantial financial awards across both stages.
During the Concept Stage, up to five winners will be selected. Each winning team will receive a prize of $100,000 to support further development of their proposed technology.
The Prototype Stage provides even larger incentives for successful participants. Up to three winners will be selected to receive prizes of $1.5 million each.
These awards are intended to help innovators advance promising technologies toward commercialization and real-world deployment.
The availability of funding at multiple stages of development reflects the organizers’ commitment to fostering innovation from concept generation through prototype validation.
For startups, researchers, and independent inventors, the competition may provide a valuable source of support for advancing technologies that could otherwise face significant funding barriers.
Open to a Diverse Range of Innovators
One of the defining characteristics of the ReadyDetect initiative is its broad eligibility criteria.
The competition welcomes applications from:
- Startups
- Established companies
- Academic research teams
- Nonprofit organizations
- Independent inventors
- Technology developers
- Scientific innovators
By encouraging participation from a wide range of organizations and individuals, the program seeks to harness expertise from multiple sectors.
Innovation in healthcare often emerges from interdisciplinary collaboration, and organizers recognize that breakthrough solutions may come from entrepreneurs, engineers, scientists, clinicians, or researchers working in a variety of environments.
This inclusive approach increases the likelihood of identifying novel technologies capable of addressing longstanding challenges in decentralized diagnostics.
Advancing the Future of Diagnostic Testing
The launch of ReadyDetect comes at a time when healthcare systems are increasingly embracing remote monitoring, at-home testing, and patient-centered care models.
Advances in diagnostics have made it possible to perform sophisticated analyses outside traditional laboratory environments, but blood collection remains a critical bottleneck for many applications. Technologies that simplify this process could unlock new opportunities for disease detection, health monitoring, and public health surveillance.
By supporting the development of low-cost, user-friendly blood collection and processing solutions, BioTools Innovator VANGUARD and BARDA aim to accelerate the transition toward more accessible and resilient diagnostic systems.
The ReadyDetect competition provides innovators with both funding opportunities and a platform to demonstrate technologies that could help shape the future of healthcare delivery.
As applications begin to arrive from researchers, entrepreneurs, and technology developers across the healthcare ecosystem, the initiative is expected to stimulate new ideas and partnerships that advance decentralized diagnostic testing. Ultimately, the program seeks to bring innovative blood collection solutions closer to real-world implementation, helping improve healthcare access while strengthening preparedness for future public health challenges.
About BioTools Innovator VANGUARD
BioTools Innovator VANGUARD is a joint initiative between BioTools Innovator and the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services.
As one of the five BARDA Accelerator Network hubs, BioTools Innovator VANGUARD serves as the Enabling Technologies Hub focusing on supporting innovations in drug discovery and development, biomanufacturing capabilities, diagnostics, and improved clinical research and care coordination. Together, the BARDA Accelerator Network hubs work to strengthen the United States’ readiness for public health emergencies.
